Molecular epidemiology and urothelial cancer

Journal of UOEH

Volumn 29, Issue 3, 2007, Pages 265-289

  Tsukino, Hiromasa ^a   Omori, Hisamitsu ^b   Kohshi, Kiyotaka ^c   Yamano, Yuko ^d   Katoh, Takahiko ^e  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d SHOWA UNIVERSITY   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Cytochrome P450; Glutathione S transferase; Molecular epidemiology; N acetyltransferase

Indexed keywords

EID: 34948835253     PISSN: 0387821X     EISSN: None     Source Type: Journal    
DOI: 10.7888/juoeh.29.265     Document Type: Article

References (134)

1. World Cancer Research Fund & American Institute for Cancer Research (1997): Cancers, nutrition and food. Nutrition and the Prevention of Cancer: a global perspective. 1st ed, Chapt 4.18, American Institute for Cancer Research, Washington, pp338-361
2. Morrison AS (1984): Advances in the etiology of urothelial cancer. Urol Clin North Am 11: 557-566
3. Silverman DT, Hartge P, Morrison AS & Devesa SS (1992): Epidemiology of bladder cancer. Hematol Oncol Clin North Am 6: 1-30
4. Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R & Miller AB (1989): Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer 44: 622-628
5. Filiadis I & Hrouda D (2000): Genetic factors in chemically-induced transitional cell bladder cancer. BJU Int 86: 794-801
6. Hoffmann D & Hoffmann I (1997): The changing cigarette, 1950-1995. J Toxicol Environ Health 50: 307-364
7. Guengerich FP & Shimada T (1991): Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4: 391-407
8. Degawa M, Stern SJ, Martin MV, Guengerich FP, Fu PP, Ilett KF, Kaderlik RK & Kadlubar FF (1994): Metabolic activation and carcinogen-DNA adduct detection in human larynx. Cancer Res 54: 4915-4919
9. Pasanen M & Pelkonen O (1994): The expression and environmental regulation of P450 enzymes in human placenta. Crit Rev Toxicol 24: 211-229
10. Boffetta P, Jourenkova N & Gustavsson P (1997): Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 8: 444-472
11. Nebert DW (1978): Genetic differences in microsomal electron transport: the Ah locus. Methods Enzymol 52: 226-240
12. Korsgaard R, Trell E, Simonsson BG, Stiksa G, Janzon L, Hood B & Oldbring J (1984): Aryl hydrocarbon hydroxylase induction levels in patients with malignant tumors associated with smoking. J Cancer Res Clin Oncol 108: 286-289
13. Hayashi S, Watanabe J, Nakachi K & Kawajiri K (1991): Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo) 110: 407-411
14. Kiyohara C, Hirohata T & Inutsuka S (1996): The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 87: 18-24
15. IARC (1999): Metabolic polymorphisms and susceptibility to cancer. 148 (P Vineis, M Malats, M Lang, A d'Errico, N Caporaso, J Cuzick & P Boffetta ed). IARC Sci, Lyon 510pp
16. Spurr NK, Gough AC, Stevenson K & Wolf CR (1987): Msp-1 polymorphism detected with a cDNA probe for the P-450I family on chromosome 15. Nucleic Acids Res 15: 5901
17. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N & Watanabe J (1990): Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 263: 131-133
18. Kiyohara C, Shirakawa T & Hopkin M (2002): Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer. Environmental Health and Preventive Medicine 7: 47-59
19. Katoh T, Inatomi H, Nagaoka A & Sugita A (1995): Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. Carcinogenesis 16: 655-657
20. Brockmoller J, Cascorbi I, Kerb R & Roots I (1996): Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56: 3915-3925
21. Bringuier PP, McCredie M, Sauter G, Bilous M, Stewart J, Mihatsch MJ, Kleihues P & Ohgaki H (1998): Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes. Int J Cancer 79: 531-536
22. Nakajima M, Yokoi T, Mitsutani M, Shin S, Kadlubar FF & Kamataki T (1994): Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3: 413-421
23. Kaderlik KR & Kadlubar FF (1995): Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. Pharmacogenetics 5: 108-117
24. Lee SW, Jang IJ, Shin SG, Lee KH, Yim DS, Kim SW, Oh SJ & Lee SH (1994): CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci 9: 482-489
25. Bartsch H, Malaveille C, Friesen M, Kadlubar FF & Vineis P (1993): Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur J Cancer 29: 1199-1207
26. Kloth MT, Gee RL, Messing EM & Swaminathan S (1994): Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis 15: 2781-2787
27. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J & Kamataki T (1999): Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90: 899-902
28. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M & Kamataki T (1999): Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125: 803-808
29. Sachse C, Brockmoller J, Bauer S & Roots I (1999): Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47: 445-449
30. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ & Broly F (2001): Five novel natural allelic variants- 951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)- of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 17: 355-356
31. Yamano S, Tatsuno J & Gonzalez FJ (1990): The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29: 1322-1329
32. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A, Anttila S, Fernandez-Salguero P, Gonzalez F & Raunio H (1999): Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 57: 1407-1413
33. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T & Kuroiwa Y (1996): Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24: 1212-1217
34. Messina ES, Tyndale RF & Sellers EM (1997): A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282: 1608-1614
35. Pianezza ML, Sellers EM & Tyndale RF (1998): Nicotine metabolism defect reduces smoking. Nature 393: 750
36. Rautio A, Kraul H, Kojo A, Salmela E & Pelkonen O (1992): Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 2: 227-233
37. Iscan M, Rostami H, Iscan M, Guray T, Pelkonen O & Rautio A (1994): Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur J Clin Pharmacol 47: 315-318
38. Miyamoto M, Umetsu Y, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Nemoto N, Sato K, Ariyoshi N & Kamataki T (1999): CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 261: 658-660
39. Kitagawa K, Kunugita N, Katoh T, Yang M & Kawamoto T (1999): The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem Biophys Res Commun 262: 146-151
40. Ariyoshi N, Takahasi Y, Miyamoto M et al (2000): Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharamacogenetics 10: 687-693
41. Ariyoshi N, Sekine H, Saito K & Kamataki T (2002): Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics 12: 501-504
42. Tsukino H, Kuroda Y, Nakao H, Imai H, Osada Y, Inatomi H, Kitagawa K, Kawamoto T & Katoh T (2002): Genetic polymorphisms of CYP2A6 and CYP2E1 with tobacco smoking is not associated with risk of urothelial cancer. Environmental Health and Preventive Medicine 7: 129-131
43. Goldstein JA (2001): Clinical relevance of genetic polymorphisms in the human CYP2C subfamily, Br J Clin Pharmacol 52: 349-355
44. Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA & Branch RA (1987): Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 47: 5488-5493
45. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA & Goldstein JA (1994): The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15419-15422
46. Zanger UM, Raimundo S & Eichelbaum M (2004): Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedberg's Arch Pharamacol 369: 23-37
47. Smith G, Stanley LA, Sim E, Strange RC & Wolf CR (1995): Metabolic polymorphisms and cancer susceptibility. Cancer Surv 25: 27-65
48. Crespi CL, Penman BW, Steimel DT, Gelboin HV & Gonzalez FJ (1991): The development of a human cell line stably expressing human CYP3A4: role in the metabolic activation of aflatoxin B1 and comparison to CYP1A2 and CYP2A3. Carcinogenesis 12: 355-359
49. Cartwright RA, Philip PA, Rogers HJ & Glashan RW (1984): Genetically determined debrisoquine oxidation capacity in bladder cancer. Carcinogenesis 5: 1191-1192
50. Horai Y, Fujita K & Ishizaki T (1989): Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol 37: 581-587
51. Benitez J, Ladero JM, Fernandez-Gundin MJ et al (1990): Polymorphic oxidation of debrisoquine in bladder cancer. Ann Med 22:157-160
52. Daly AK, Brockmoller J, Broly F et al (1996): Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193-201
53. Laforest L, Wikman H, Benhamou S, Saarikoski ST, Bouchardy C, Hirvonen A, Dayer P & Husgafvel-Pursiainen K (2000): CYP2D6 gene polymorphism in Caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships. Eur J Cancer 36: 1825-1832
54. Spurr NK, Gough AC, Chinegwundoh FI & Smith CA (1995): Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Clin Chem 41: 1864-1869
55. Anwar WA, Abdel-Rahman SZ, El-Zein RA, Mostafa HM & Au WW (1996): Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 17: 1923-1929
56. Wolf CR, Smith CA, Gough AC et al (1992): Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13: 1035-1038
57. Chinegwundoh FI & Kaisary AV (1996) Polymorphism and smoking in bladder Carcinogenesis. Br J Urol 77: 672-675
58. Tanaka E, Terada M & Misawa S (2000): Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 25: 165-175
59. McBride OW, Umeno M, Gelboin HV & Gonzalez FJ (1987): A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucleic Acids Res 15: 10071
60. Uematsu F, Kikuchi H, Ohmachi T, Sagami I, Motomiya M, Kamataki T, Komori M & Watanabe M (1991): Two common RFLPs of the human CYP2E gene. Nucleic Acids Res 19: 2803
61. Farker K, Lehmann MH, Kastner R, Hoffmann A, Janitzky V, Schubert J, Matz U & Hofmann W (1998): CYP2E1 genotyping in renal cell/urothelial cancer patients in comparison with control populations. Int J Clin Pharmacol Ther 36: 463-468
62. Farker K, Lehmann MH, Kastner R, Weber J, Janitzky V, Schubert J & Hoffmann A (2000): Analysis of point mutation in exon 2 of CYP2E1 gene in renal cell/urothelial cancer patients in comparison with control population. Int J Clin Pharmacol Ther 38: 30-34
63. Hayes JD & Pulford DJ (1995): The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600
64. Mannervik B, Awasthi YC, Board PG et al (1992): Nomenclature for human glutathione transferases. Biochem J 282 (Pt 1): 305-306
65. Seidegard J, Vorachek WR, Pero RW & Pearson WR (1988): Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85: 7293-7297
66. Zhong S, Wyllie AH, Barnes D, Wolf CR & Spurr NK (1993): Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14: 1821-1824
67. Daly AK, Thomas DJ, Cooper J, Pearson WR, Neal DE & Idle JR (1993): Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. BMJ 307: 481-482
68. Lafuente A, Pujol F, Carretero P, Villa JP & Cuchi A (1993): Human glutathione S-transferase mu (GST mu) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett 68: 49-54
69. Bell DA, Taylor JA, Paulson DF, Robertson CN, Monier JL & Lucier GW (1993): Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85: 1159-1164
70. Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK & Hardy S (1994): Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 15: 1077-1081
71. Brockmoller J, Kerb R, Drakoulis N, Staffeldt B & Roots I (1994): Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res 54: 4103-4111
72. Rothman N, Hayes RB, Zenser TV et al (1996): The glutathione S-transferase M1 (GSTM1) null genotype and benzidine-associated bladder cancer, urine mutagenicity, and exfoliated urothelial cell DNA adducts. Cancer Epidemiol Biomarkers Prev 5: 979-983
73. Lafuente A, Zakahary MM, el-Aziz MA, Ascaso C, Lafuente MJ, Trias M & Carretero P (1996): Influence of smoking in the glutathione-S-transferase M1 deficiency-associated risk for squamous cell carcinoma of the bladder in schistosomiasis patients in Egypt. Br J Cancer 74: 836-838
74. Okkels H, Sigsgaard T, Wolf H & Autrup H (1996): Glutathione S-transferase mu as a risk factor in bladder tumours. Pharmacogenetics 6: 251-256
75. Kempkes M, Golka K, Reich S, Reckwitz T & Bolt HM (1996): Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71: 123-126
76. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Mostafa HM & Au WW (1998): GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Cancer Detect Prev 22: 129-138
77. Katoh T, Inatomi H, Kim H, Yang M, Matsumoto T & Kawamoto T (1998): Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. Cancer Lett 132: 147-152
78. Salagovic J, Kalina I, Habalova V, Hrivnak M, Valansky L & Biros E (1999): The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer. Physiol Res 48: 465-471
79. Georgiou I, Filiadis F, Alamanos Y, Bouha I, Giannakopoulos X & Lolis D (2000): Glutathione S-transferase null genotypes in transitional cell bladder cancer: a case-control study. Eur Urol 37: 660-664
80. Kim WJ, Lee HL, Lee SC, Kim YT & Kim H (2000): Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol 164: 209-213
81. Martone T, Vineis P, Malaveille C & Terracini B (2000): Impact of polymorphisms in xeno(endo)biotic metabolism on pattern and frequency of p53 mutations in bladder cancer. Mutat Res 462: 303-309
82. Mungan NA, Aben KK, Beeks E, Kampman E, Bunschoten A, Bussemakers M, Witjes JA & Kiemeney LA (2000): A germline homozygote deletion of the glutathione-S-transferase Mul gene predisposes to bladder cancer. Urol Int 64: 134-138
83. Peluso M, Airoldi L, Magagnotti C, Fiorini L, Munnia A, Hautefeuille A, Malaveille C & Vineis P (2000): White blood cell DNA adducts and fruit and vegetable consumption in bladder cancer. Carcinogenesis 21: 183-187
84. Schnakenberg E, Lustig M, Breuer R, Werdin R, Hubotter R, Dreikorn K & Schloot W (2000): Gender-specific effects of NAT2 and GSTM1 in bladder cancer. Clin Genet 57: 270-277
85. Steinhoff C, Franke KH, Golka K, Their R, Romer HC, Rotzel C, Ackermann R & Schulz WA (2000): Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol 74: 521-526
86. Aktas D, Ozen H, Atsu N, Tekin A, Sozen S & Tuncbilek E (2001): Glutathione S-transferase M1 gene polymorphism in bladder cancer patients, A marker for invasive bladder cancer. Cancer Genet Cytogenet 125: 1-4
87. Toruner GA, Akyerli C, Ucar A, Aki T, Atsu N, Ozen H, Tez M, Cetinkaya M & Ozcelik T (2001): Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol 75: 459-464
88. Lee SJ, Cho SH, Park SK et al (2002): Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. Cancer Lett 177: 173-179
89. Johns LE & Houlston RS (2000): Glutathione S-transferase mul (GSTM1) status and bladder cancer risk: a meta-analysis. Mutagenesis 15: 399-404
90. Engel LS, Taioli E, Pfeiffer R et al (2002): Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 156: 95-109
91. Harries LW, Stubbins MJ, Forman D, Howard GC & Wolf CR (1997): Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18: 641-644
92. Katoh T, Kaneko S, Takasawa S, Nagata N, Inatomi H, Ikemura K, Itoh H, Mastumoto T, Kawamoto T & Bell DA (1999): Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics 9: 165-169
93. Kadlubar FF & Badawi AF (1995): Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Toxicol Lett 82-83: 627-632
94. Katoh T, Inatomi H, Yang M, Kawamoto T, Matsumoto T & Bell DA (1999): Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics 9: 401-404
95. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler JL & Bell DA (1998): The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 58: 3603-3610
96. Okkels H, Sigsgaard T, Wolf H & Autrup H (1997): Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 6: 225-231
97. Hsieh FI, Pu YS, Chern HD, Hsu LI, Chiou HY & Chen CJ (1999): Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br J Cancer 81: 537-541
98. Cascorbi I, Roots I & Brockmoller J (2001): Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 61: 5051-5056
99. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE & Bryan GT(1979): N-acetyl-transferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 29: 71-79
100. Wolf H, Lower GM & Bryan GT Jr (1980): Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol 14: 161-165
101. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E & Kahn MA (1982): Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 8303: 842-845
102. Evans DA, Eze LC & Whibley EJ (1983): The association of the slow acetylator phenotype with bladder cancer. J Med Genet 20: 330-333
103. Miller ME & Cosgriff JM (1983): Acetylator phenotype in human bladder cancer. J Urol 130: 65-66
104. Cartwright R (1984): Epidemiologic studies on N-acetylation and C-center ring oxidation in neoplasia. In: Banbury Report 16: Genetic Variability in Responses to Chemical Exposure, (Omenn GS, Gelboin HV, ed). Cold Spring Harbor Laboratory, Cold Spring Harbor pp359-368
105. Hanssen HP, Agarwal DP, Goedde HW, Bucher H, Huland H, Brachmann W & Ovenbeck R (1985): Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population. Eur Urol 11: 263-266
106. Ladero JM, Kwok CK, Jara C, Fernandez L, Silmi AM, Tapia D & Uson AC (1985): Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 17: 96-99
107. Mommsen S, Barfod NM & Aagaard J (1985): N-acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 6: 199-201
108. Karakaya AE, Cok I, Sardas S, Gogus O & Sardas OS (1986): N-acetyltransferase phenotype of patients with bladder cancer. Hum Toxicol 5: 333-335
109. Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA & Branch RA (1987): Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 47: 5488-5493
110. Bicho MP, Breitenfeld L, Carvalho AA & Manso CF (1988): Acetylation phenotypes in patients with bladder carcinoma. Ann Genet 31: 167-171
111. Horai Y, Fujita K & Ishizaki T (1989): Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol 37: 581-587
112. Hanke J & Krajewska B (1990): Acetylation phenotypes and bladder cancer. J Occup Med 32: 917-918
113. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, You X, Yin S, Woosley RL & Meyer UA (1993): N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 14: 675-678
114. Dewan A, Chattopadhyay P & Kulkarni PK (1995): N-acetyltransferase activity - a susceptibility factor in human bladder carcinogenesis. Indian J Cancer 32: 15-19
115. Ishizu S, Hashida C, Hanaoka T, Maeda K & Ohishi Y (1995): N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. Jpn J Cancer Res 86: 1179-1181
116. Risen A, Wallace DM, Bathers S & Sim E (1995): Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4: 231-236
117. Golka K, Prior V, Blaszkewicz M, Cascorbi I, Schops W, Kierfeld G, Roots I & Bolt HM (1996): Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health 22: 332-338
118. Okkels H, Sigsgaard T, Wolf H & Autrup H (1997): Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 6: 225-231
119. Peluso M, Airoldi L, Armelle M, Martone T, Coda R, Malaveille C, Giacomelli G, Terrone C, Casetta G & Vineis P (1998): White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 7: 341-346
120. Schnakenberg E, Ehlers C, Feyerabend W, Werdin R, Hubotter R, Dreikorn K & Schloot W (1998): Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients. Clin Genet 53: 396-402
121. Su HJ, Guo YL, Lai MD, Huang JD, Cheng Y & Christiani DC (1998): The NAT2* slow acetylator genotype is associated with bladder cancer in Taiwanese, but not in the black foot disease endemic area population. Pharmacogenetics 8: 187-190
122. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler JL & Bell DA (1998): The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 58: 3603-3610
123. Filiadis IF, Georgiou I, Alamanos Y, Kranas V, Giannakopoulos X & Lolis D (1999): Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J Urol 161: 1672-1675
124. Inatomi H, Katoh T, Kawamoto T & Matsumoto T (1999): NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol 6: 446-454
125. Cascorbi I, Roots I & Brockmoller J (2001): Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer, significantly reduced risk in subjects with NAT1*10. Cancer Res 61: 5051-5056
126. Kontani K, Kawakami M, Nakajima T & Katsuyama T (2001): Tobacco use and occupational exposure to carcinogens, but not N-acetyltransferase 2 genotypes are major risk factors for bladder cancer in the Japanese. Urol Res 29: 199-204
127. Green J, Banks E, Berrington A, Darby S, Deo H & Newton R (2000): N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer 83: 412-417
128. Johns LE & Houlston RS (2000): N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environ Mol Mutagen 36: 221-227
129. Marcus PM, Vineis P & Rothman N (2000): NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 10: 115-122
130. Marcus PM, Hayes RB, Vineis P et al (2000): Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 9: 461-467
131. Vineis P, Marinelli D, Autrup H et al (2001): Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 10: 1249-1252
132. Hung RJ, Boffetta P & Brennan P et al (2004): GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 110: 598-604
133. Tsukino H, Kuroda Y, Nakao H, Imai H, Inatomi H, Osada Y & Katoh T (2004): Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol 130: 99-106
134. Bartsch H, Nair U, Risch A, Rojas M, Wikman H & Alexandrov K (2000): Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9: 3-28